Skip to main content
Clinical Trials/NCT00236249
NCT00236249
Completed
Phase 3

Evaluation of Lidocaine Continuous Intravenous Administration for Postoperative Recovery After Colorectal Surgery

Assistance Publique - Hôpitaux de Paris1 site in 1 country110 target enrollmentMay 2005

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Colorectal Neoplasms
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
110
Locations
1
Primary Endpoint
Readiness for discharge, checked twice a day
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

The purpose of this study is to check if lidocaine intravenous administration during surgery and 24 hours after surgery, associated with standardised management of the patient, helps to accelerate recovery and to improve the quality of recovery, after surgery for colic or rectal neoplasms.

Detailed Description

One of the purposes of postoperative care is to shorten the duration of recovery, in order to reduce the complications and to improve the quality of life. After abdominal surgery, two factors can be modified: early mobilisation, thanks to optimal pain control, and return to a normal feeding, permitted by transit recovery. Opioids, which are usually used for pain control, delay the intestinal transit and can be responsible for side effects like drowsiness, nausea, urine retention. Lidocaine is a local anaesthetic, which means that it can stop the pain if it is administrated around the nerves. It can also be used intravenously. In this way, it is supposed to decrease opioid consumption, accelerate intestinal transit and even decrease inflammation. Side effects of lidocaine appear at higher plasma concentrations than those considered in the study. After randomisation, the patient will receive either intravenous lidocaine during the surgery and 24 hours after the surgery, or physiological serum (like placebo). Every patient will dispose of patient-controlled-analgesia with morphine and of a standardised care management. Data will be collected concerning pain level, morphine consumption, psychomotor performances, duration of ileus, speed of activity recovery, quality of recovery, and side effects. Biological evaluation of lidocaine concentration and inflammation will also be done.

Registry
clinicaltrials.gov
Start Date
May 2005
End Date
May 2007
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Colorectal neoplasm
  • Radical surgery
  • Median incision

Exclusion Criteria

  • American Society of Anesthesiologists (ASA) score equal to or up to 3
  • Unwilling or unable to use patient-controlled analgesia (PCA)
  • Chronic consumption of opioids
  • Chronic drug or alcohol abuse
  • Chronic pain
  • Unable to read or write text
  • Inflammatory disease of intestinal tract
  • Allergy to morphine
  • Allergy to lidocaine
  • Severe atrioventricular conduction dysfunction without stimulator

Outcomes

Primary Outcomes

Readiness for discharge, checked twice a day

Secondary Outcomes

  • Clinical side effects twice a day
  • Pain every 4 hours the first day after surgery, then twice a day
  • Morphine consumption: dose of titration, then twice a day
  • Time of transit recovery
  • Physical rehabilitation score daily
  • Psychomotor test daily until reaching of preoperative values
  • Quality of recovery score at 1st, 3rd, and 6th day
  • Satisfaction score at discharge
  • Biological inflammation the day before the surgery, then at 1st, 3rd, and 6th day
  • Lidocaine concentration at the end of surgery and 24 hours forward

Study Sites (1)

Loading locations...

Similar Trials